NCT02292186View on ClinicalTrials.gov

A Extension Study to Evaluate Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Cardiac Amyloidosis

PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

February 22, 2017

Study Completion Date

February 22, 2017

Conditions
TTR-mediated Amyloidosis
Interventions
DRUG

Revusiran (ALN-TTRSC)

Trial Locations (5)

10034

Clinical Trial Site, New York

44195

Clinical Trial Site, Cleveland

02155

Clinical Trial Site, Boston

Unknown

Clinical Trial Site, Calgary

UK NW3 2PF

Clinical Trial Site, London

Sponsors
All Listed Sponsors
lead

Alnylam Pharmaceuticals

INDUSTRY